Section Arrow
Quote
UTHR.NASDAQ
- United Therapeutics Corp
Quotes are at least 15-min delayed:2025/09/14 14:17 EDT
Regular Hours
Last
 405.02
+0.18 (+0.04%)
Day High 
407.055 
Prev. Close
404.84 
1-M High
436.95 
Volume 
626.42K 
Bid
383
Ask
410
Day Low
399.795 
Open
401.44 
1-M Low
292.34 
Market Cap 
18.31B 
Currency USD 
P/E 15.8 
%Yield -- 
10-SMA 378.9 
20-SMA 344.54 
50-SMA 316.13 
52-W High 436.95 
52-W Low 266.98 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
25.63/29.07
Enterprise Value
18.61B
Balance Sheet
Book Value Per Share
158.62
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
2.88B
Operating Revenue Per Share
48.74
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands1.12+0.06+5.66%-- 
IXHLIncannex Healthcare0.5475+0.0175+3.30%-- 
CGCCanopy Growth Corp1.37-0.02-1.44%-- 
VTRSViatris9.96-0.21-2.06%227.2PE
TEVATeva Pharmaceutical Industries Limited19.93+0.04+0.20%-- 
Quotes are at least 15-min delayed：2025/09/14 14:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.